No results for ‘’
Inspirisys Solutions Ltd
₹83.83
(3.82%)
Mon, 05 Oct 2026, 09:24 pm
Technology Services
Information Technology Services
24.5KInspirisys Solutions EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 9.81 | 27.37 | 15.37 | 18.25 | 9.13 | 23.11 | 51.73 | 24.38 | 0 | 0 | 0 | 0 | 240.22 | 32.66 | 0 | 0 | 0 | 113.66 | 9.36 |
| Price to book ratio | 0 | 1.33 | 1.91 | 0.97 | 0.98 | 0.81 | 0.90 | 0.62 | 1.04 | 1.64 | 0 | 0 | 0 | 0 | 4.60 | 11.41 | 293.87 | 0 | 14.20 | 5.08 |
| Price to sales ratio | 0 | 0.63 | 0.70 | 0.36 | 0.40 | 0.24 | 0.18 | 0.16 | 0.26 | 0.41 | 0.29 | 0.44 | 0.33 | 0.29 | 0.17 | 0.43 | 0.68 | 0.47 | 0.85 | 0.77 |
| Price to cash flow ratio | 0 | 6.37 | 17.45 | 467.14 | 9.09 | 0 | 0 | 3.76 | 0 | 21.19 | 0 | 0 | 4.54 | 0 | 2.52 | 2.80 | 0 | 15.51 | 21.05 | 9.38 |
| Enterprise value | 0 | 143Cr | 213Cr | 118Cr | 115Cr | 155Cr | 177Cr | 147Cr | 229Cr | 355Cr | 345Cr | 449Cr | 335Cr | 327Cr | 205Cr | 242Cr | 319Cr | 248Cr | 440Cr | 303Cr |
| Enterprise value to EBITDA ratio | 0 | 5.93 | 0.88 | 5.34 | 10.33 | 6.27 | 5.86 | 5.06 | 6.38 | 7.18 | 21.35 | 15.12 | 0 | 13.55 | 9.58 | 20.74 | 0 | 8.30 | 12.77 | 9.01 |
| Debt to equity ratio | 0.82 | 0.49 | 0.33 | 0.32 | 0.40 | 0.79 | 1.03 | 1.10 | 1.08 | 1.61 | 0 | 0 | 0 | 0 | 8.03 | 6.45 | 138.13 | 0 | 2.83 | 1.44 |
| Return on equity % | 0 | 14.86 | 7 | 6.44 | 5.43 | 9.10 | 3.55 | 1.21 | 4.06 | -0.77 | -295.25 | 0 | 0 | 0 | 80.07 | -17.38 | -166.02 | 0 | 156.41 | 60.19 |
Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio
The Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Inspirisys Solutions Ltd's valuation, profitability, and overall financial performance. Tracking the Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Inspirisys Solutions Ltd (NSE: INSPIRISYS, BSE: 532774) is currently trading at ₹83.83, with a market capitalization of ₹336.27Cr. As a leading company in the Technology services sector and Information technology services industry, monitoring the Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio Current Value
The current Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio stands at 9.01.
The Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 9.01
- 2023: 12.77
- 2022: 8.30
- 2021: 0
- 2020: 20.74
The decline in Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Inspirisys Solutions Ltd.
Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Inspirisys Solutions Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.